Stock in Focus

18 April 23

FII & DII DATA 

FII Net  SELL- 810.60cr
DII Net  BUY - 401.66cr

19 April 2023

Today Results 
Mastek
Alok IND
Guj Hotels
Benares Hotels
ICICI Securitie
Tata Comm

Stocks in Focus, Stock Market News

Crisil 

reported a consolidated profit of Rs 145.8 crore in the first quarter of FY23, up 19.8 percent from the year-ago period but the net profit and operating margins saw some contraction, the company said on April 18.
The net profit margin for the quarter ended March 31, 2023 came in at 20.38 percent, down six basis points (bps) from 20.44 percent in the corresponding period of the last fiscal. One basis point is one-hundredth of a percentage point.


State Bank of India 

The state-owned lender on Tuesday said the board has approved raising up to $2 billion via long-term debt.


Tata Coffee 

Tata Group-subsidiary's consolidated net profit rose 19.7 percent  to Rs 48.8 crore compared to Rs 41 crore, in the same quarter last year. The revenue came at Rs 723 crore vs Rs 656.3 crore on a yearly basis — an increase of more than 10 percent.


ICICI Lombard 

Private sector general insurer on Tuesday reported a 39.6 percent year-on-year rise in net profit at Rs 437 crore for the fourth quarter that ended March 31, 2023. In the corresponding quarter last year, the company posted a net profit of Rs 313 crore.


Prestige Estates 

Realty firm on Tuesday said its wholly owned subsidiary Prestige Exora Business Parks Ltd has acquired a 51 percent stake in Dashanya Tech Parkz Private Ltd for Rs 66 crore. Dashanya Tech Parkz is engaged in the business of the development and construction of commercial office space.


Bank of India 

Public sector bank's board approved the raising of capital for the FY24 aggregating up to Rs 6,500 crore. The Mumbai-headquartered bank plans to raise up to Rs 4,500 crore by issuing fresh equity capital in the form of FPO/QIP/Rights Issue/Preferential Issue and/or Basel III compliant Additional Tier-1 (AT-1) bonds (domestic and foreign currency).


Zydus Lifesciences 

The company received the final approval from the US Food and Drug Administration (FDA) to manufacture and market Estradiol Transdermal System. Estradiol transdermal system is used in the prevention of postmenopausal osteoporosis. The company said the drug will be manufactured at the group’s formulation manufacturing facility in Moraiya, Ahmedabad.


Piramal Pharma 

Pharmaceutical major on Tuesday said the United States Food and Drug Administration (US FDA) has concluded its inspection of Sellersville, US-based manufacturing facility. The company revealed that the US FDA issued an EIR for its Sellersville manufacturing facility. The inspection was conducted between December 19, 2022, and January 13, 2023.